Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor (VX-770) in Cystic Fibrosis with G551D Mutation
NCT00457821Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2007
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ivacaftor in cystic fibrosis (CF) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Subjects With Adverse Events. Started May 2007; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00457821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00457821.